Chemed Q2 FY26 GAAP diluted EPS climbs 43.7% to $5.13; revenue increases 8.8% to $673.3 million

Reuters2026/07/28 20:32

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Chemed posted Q2 revenue of $673.3 million, up 8.8%, with GAAP diluted EPS of $5.13, up 43.7%.
VITAS net patient revenue climbed 11.9% to $443.3 million; average daily census rose 6.1% to 23,687.
VITAS recorded $500,000 in Medicare Cap billing limitation versus $16.4 million a year earlier; no Florida cap is expected in 2026.
Roto-Rooter revenue increased 3.3% to $229.9 million; adjusted EBITDA was $48.5 million, essentially flat, with margin down 0.77 percentage point to 21.1%.
2026 adjusted diluted EPS guidance increased to $25.00-$25.75 from $24.00-$24.75, mainly on VITAS outperformance; Roto-Rooter outlook unchanged.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemed Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000019584-26-000018), on July 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Chemed Q2 FY26 GAAP diluted EPS climbs 43.7% to $5.13; revenue increases 8.8% to $673.3 million

You may also like

Crypto prices